Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Autoimmunity to bactericidal/permeability-increasing protein in bronchiectasis exhibits a requirement for Pseudomonas aeruginosa IgG response.

Skopelja-Gardner S, Theprungsirikul J, Meagher RE, Beliveau CM, Bradley KE, Avery M, Henkle E, Siegel S, Gifford AH, Winthrop KL, Rigby WFC.

Eur Respir J. 2019 Feb 7;53(2). pii: 1801891. doi: 10.1183/13993003.01891-2018. Print 2019 Feb. No abstract available.

PMID:
30385530
2.

Triple Positivity for Anti-Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti-Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis: Implications for Very Early Identification of At-Risk Individuals.

Verheul MK, Böhringer S, van Delft MAM, Jones JD, Rigby WFC, Gan RW, Holers VM, Edison JD, Deane KD, Janssen KMJ, Westra J, Brink M, Rantapää-Dahlqvist S, Huizinga TWJ, van der Helm-van Mil AHM, van der Woude D, Toes REM, Trouw LA.

Arthritis Rheumatol. 2018 Nov;70(11):1721-1731. doi: 10.1002/art.40562. Epub 2018 Sep 16.

PMID:
29781231
3.

Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.

Kremer JM, Rigby W, Singer NG, Birchwood C, Gill D, Reiss W, Pei J, Michalska M.

Arthritis Rheumatol. 2018 Aug;70(8):1200-1208. doi: 10.1002/art.40493. Epub 2018 Jun 14.

PMID:
29575803
4.

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs.

Rigby WFC, Lampl K, Low JM, Furst DE.

Int J Rheumatol. 2017;2017:9614241. doi: 10.1155/2017/9614241. Epub 2017 Oct 31. Review.

5.

"NETtling" the host: Breaking of tolerance in chronic inflammation and chronic infection.

Skopelja-Gardner S, Jones JD, Rigby WFC.

J Autoimmun. 2018 Mar;88:1-10. doi: 10.1016/j.jaut.2017.10.008. Review.

PMID:
29100671
6.

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.

Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS.

N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977.

7.

Editorial: Anti-Citrullinated Protein Antibody, Anti-Carbamylated Protein Antibody, and Rheumatoid Arthritis: Azurophilic Granules Sing the Blues.

Rigby WFC, Skopelja-Gardner S, Jones JD.

Arthritis Rheumatol. 2017 Dec;69(12):2251-2255. doi: 10.1002/art.40238. No abstract available.

8.

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.

Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, Biswas P, Needle E, Passador S, Mojcik CF, Rigby WF.

Arthritis Rheumatol. 2017 Oct;69(10):1969-1977. doi: 10.1002/art.40187. Epub 2017 Sep 6.

9.

Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.

Skopelja-Gardner S, Jones JD, Hamilton BJ, Danilov AV, Rigby WFC.

J Immunol. 2017 Aug 15;199(4):1275-1282. doi: 10.4049/jimmunol.1602105. Epub 2017 Jul 14.

10.

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.

Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Blanco R, Kadva A, Dimonaco S.

Ann Rheum Dis. 2017 Jul;76(7):1279-1284. doi: 10.1136/annrheumdis-2016-210561. Epub 2017 Apr 7.

11.

Brief Report: Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis Patients Are Reactive With Specific Epitopes of the Human Fibrinogen β-Chain.

Jones JD, Hamilton BJ, Rigby WFC.

Arthritis Rheumatol. 2017 Jul;69(7):1381-1386. doi: 10.1002/art.40098. Epub 2017 Jun 5.

12.

Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission.

Pelzek AJ, Grönwall C, Rosenthal P, Greenberg JD, McGeachy M, Moreland L, Rigby WFC, Silverman GJ.

Arthritis Rheumatol. 2017 Jun;69(6):1176-1186. doi: 10.1002/art.40053. Epub 2017 May 3.

13.

Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.

Moots RJ, Sebba A, Rigby W, Ostor A, Porter-Brown B, Donaldson F, Dimonaco S, Rubbert-Roth A, van Vollenhoven R, Genovese MC.

Rheumatology (Oxford). 2017 Apr 1;56(4):541-549. doi: 10.1093/rheumatology/kew370. Review.

14.

The role for neutrophil extracellular traps in cystic fibrosis autoimmunity.

Skopelja S, Hamilton BJ, Jones JD, Yang ML, Mamula M, Ashare A, Gifford AH, Rigby WF.

JCI Insight. 2016 Oct 20;1(17):e88912.

15.

Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.

Monaco WE, Jones JD, Rigby WF.

Clin Rheumatol. 2016 Oct;35(10):2457-62. doi: 10.1007/s10067-016-3313-y. Epub 2016 May 21. Review.

PMID:
27209045
16.

Anti-carbamylated Protein Antibody Levels Correlate with Anti-Sa (Citrullinated Vimentin) Antibody Levels in Rheumatoid Arthritis.

Challener GJ, Jones JD, Pelzek AJ, Hamilton BJ, Boire G, de Brum-Fernandes AJ, Masetto A, Carrier N, Ménard HA, Silverman GJ, Rigby WFC.

J Rheumatol. 2016 Feb;43(2):273-281. doi: 10.3899/jrheum.150179. Epub 2015 Dec 15.

17.

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.

Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N.

Ann Rheum Dis. 2016 Jun;75(6):1081-91. doi: 10.1136/annrheumdis-2015-207628. Epub 2015 Oct 28.

18.

Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.

Smolen JS, Weinblatt ME, van der Heijde D, Rigby WF, van Vollenhoven R, Bingham CO 3rd, Veenhuizen M, Gill A, Zhao F, Komocsar WJ, Berclaz PY, Ortmann R, Lee C.

Ann Rheum Dis. 2015 Aug;74(8):1567-70. doi: 10.1136/annrheumdis-2014-207090. Epub 2015 Apr 14.

PMID:
25873635
19.

Does bracing affect bone health in women with adolescent idiopathic scoliosis?

Akseer N, Kish K, Rigby WA, Greenway M, Klentrou P, Wilson PM, Falk B.

Scoliosis. 2015 Feb 18;10:5. doi: 10.1186/s13013-015-0031-1. eCollection 2015.

20.

Adolescent idiopathic scoliosis: the possible harm of bracing and the likely benefit of exercise.

Falk B, Rigby WA, Akseer N.

Spine J. 2015 Jan 1;15(1):209-10. doi: 10.1016/j.spinee.2014.08.009. No abstract available.

PMID:
25511673
21.

Reply: To PMID 24719284.

Mecchella J, Rigby WF, Zbehlik AJ.

Arthritis Care Res (Hoboken). 2015 May;67(5):737-8. doi: 10.1002/acr.22521. No abstract available.

22.

Induction of interleukin-6 production by rituximab in human B cells.

Jones JD, Hamilton BJ, Skopelja S, Rigby WF.

Arthritis Rheumatol. 2014 Nov;66(11):2938-46. doi: 10.1002/art.38798.

23.

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.

Pritchard CH, Greenwald MW, Kremer JM, Gaylis NB, Rigby W, Zlotnick S, Chung C, Jaber B, Reiss W; RATE-RA Study Group.

BMC Musculoskelet Disord. 2014 May 24;15:177. doi: 10.1186/1471-2474-15-177.

24.

Adolescent idiopathic scoliosis: the possible harm of bracing and the likely benefit of exercise.

Falk B, Rigby WA, Akseer N.

Spine J. 2015 Jun 1;15(6):1169-71. doi: 10.1016/j.spinee.2014.05.006. Epub 2014 May 16. No abstract available.

PMID:
24846846
25.

Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels.

Jones JD, Hamilton BJ, Challener GJ, de Brum-Fernandes AJ, Cossette P, Liang P, Masetto A, Ménard HA, Carrier N, Boyle DL, Rosengren S, Boire G, Rigby WF.

Arthritis Res Ther. 2014 Apr 25;16(2):R103. doi: 10.1186/ar4552.

26.

Pancytopenia and cough in a man with amyopathic dermatomyositis.

Mecchella JN, Rigby WF, Zbehlik AJ.

Arthritis Care Res (Hoboken). 2014 Oct;66(10):1587-90. doi: 10.1002/acr.22345. No abstract available.

27.

Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.

Emery P, Rigby W, Tak PP, Dörner T, Olech E, Martin C, Millar L, Travers H, Fisheleva E.

PLoS One. 2014 Feb 3;9(2):e87379. doi: 10.1371/journal.pone.0087379. eCollection 2014.

28.

Depletion of hnRNP A2/B1 overrides the nuclear retention of the HIV-1 genomic RNA.

Gordon H, Ajamian L, Valiente-Echeverrìa F, Lévesque K, Rigby WF, Mouland AJ.

RNA Biol. 2013 Nov;10(11):1714-25. doi: 10.4161/rna.26542. Epub 2013 Sep 30.

29.

Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.

Rigby WF, Mease PJ, Olech E, Ashby M, Tole S.

J Rheumatol. 2013 May;40(5):599-604. doi: 10.3899/jrheum.120924. Epub 2013 Apr 1.

30.

A rheumatoid factor paradox: inhibition of rituximab effector function.

Jones JD, Shyu I, Newkirk MM, Rigby WF.

Arthritis Res Ther. 2013 Jan 25;15(1):R20. doi: 10.1186/ar4152.

31.

Reply: To PMID 22674374.

Jones JD, Hamilton BJ, Rigby WF.

Arthritis Rheum. 2013 Apr;65(4):1132-3. doi: 10.1002/art.37870. No abstract available.

32.

Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.

Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, Singh N, Lepley D, Genovese MC.

Arthritis Care Res (Hoboken). 2013 Mar;65(3):362-71. doi: 10.1002/acr.21847.

33.

Design and performance of a new induction furnace for heat treatment of superconducting radiofrequency niobium cavities.

Dhakal P, Ciovati G, Rigby W, Wallace J, Myneni GR.

Rev Sci Instrum. 2012 Jun;83(6):065105. doi: 10.1063/1.4725589.

PMID:
22755660
34.

Rituximab mediates loss of CD19 on B cells in the absence of cell death.

Jones JD, Hamilton BJ, Rigby WF.

Arthritis Rheum. 2012 Oct;64(10):3111-8. doi: 10.1002/art.34560.

35.

Unusual case of a swollen painful toe in a young man.

Jones JD, Albert DA, Thadani V, Rigby WF.

Arthritis Care Res (Hoboken). 2012 Feb;64(2):298-302. doi: 10.1002/acr.20603. No abstract available.

36.

Increased frequency of complement C4B deficiency in rheumatoid arthritis.

Rigby WF, Wu YL, Zan M, Zhou B, Rosengren S, Carlson C, Hilton W, Yu CY.

Arthritis Rheum. 2012 May;64(5):1338-44. doi: 10.1002/art.33472.

37.

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.

Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T.

Ann Rheum Dis. 2012 Mar;71(3):351-7. doi: 10.1136/annrheumdis-2011-200170. Epub 2011 Oct 19.

38.

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.

Rigby W, Tony HP, Oelke K, Combe B, Laster A, von Muhlen CA, Fisheleva E, Martin C, Travers H, Dummer W.

Arthritis Rheum. 2012 Feb;64(2):350-9. doi: 10.1002/art.33317.

39.

Closing the Gap: cultural safety in Indigenous health education.

Rigby W, Duffy E, Manners J, Latham H, Lyons L, Crawford L, Eldridge R.

Contemp Nurse. 2010 Dec-2011 Jan;37(1):21-30. doi: 10.5172/conu.2011.37.1.021.

PMID:
21591823
40.

Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.

Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A.

Arthritis Care Res (Hoboken). 2011 May;63(5):711-20. doi: 10.1002/acr.20419.

41.

A flexible approach to studying post-transcriptional gene regulation in stably transfected mammalian cells.

Nichols RC, Botson J, Wang XW, Hamilton BJ, Collins JE, Uribe V, Brooks SA, Zan M, Rigby WF.

Mol Biotechnol. 2011 Jul;48(3):210-7. doi: 10.1007/s12033-010-9360-8.

42.

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.

Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM; IMAGE Investigators.

Ann Rheum Dis. 2011 Jan;70(1):39-46. doi: 10.1136/ard.2010.137703. Epub 2010 Oct 11.

PMID:
20937671
43.

Ichthyotic-appearing skin changes associated with childhood morphea, systemic sclerosis, and systemic lupus erythematosus/scleroderma overlap.

Williams CM, Storm CA, Burns C, Rigby W, Dinulos JG.

Pediatr Dermatol. 2010 Mar-Apr;27(2):170-3. doi: 10.1111/j.1525-1470.2010.01108.x.

PMID:
20537069
44.

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study.

Østergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S.

Arthritis Rheum. 2010 Aug;62(8):2227-38. doi: 10.1002/art.27524.

45.

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).

Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H.

Ann Rheum Dis. 2010 Sep;69(9):1629-35. doi: 10.1136/ard.2009.119933. Epub 2010 May 20. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

46.

Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA.

Antiochos BB, Brown LA, Li Z, Tosteson TD, Wortmann RL, Rigby WF.

J Rheumatol. 2009 Dec;36(12):2704-10. doi: 10.3899/jrheum.090549. Epub 2009 Nov 16.

47.

Separate cis-trans pathways post-transcriptionally regulate murine CD154 (CD40 ligand) expression: a novel function for CA repeats in the 3'-untranslated region.

Hamilton BJ, Wang XW, Collins J, Bloch D, Bergeron A, Henry B, Terry BM, Zan M, Mouland AJ, Rigby WF.

J Biol Chem. 2008 Sep 12;283(37):25606-16. doi: 10.1074/jbc.M802492200. Epub 2008 Jul 18.

48.

PILAR is a novel modulator of human T-cell expansion.

Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Engle XA, Rigby WF, Pioli PA, Guyre PM, Conejo-Garcia JR.

Blood. 2008 Aug 15;112(4):1259-68. doi: 10.1182/blood-2007-12-130773. Epub 2008 Jun 12.

49.

Role of the RNA-binding protein tristetraprolin in glucocorticoid-mediated gene regulation.

Ishmael FT, Fang X, Galdiero MR, Atasoy U, Rigby WF, Gorospe M, Cheadle C, Stellato C.

J Immunol. 2008 Jun 15;180(12):8342-53.

50.

Supplemental Content

Support Center